Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

The HAS-BLED Score and Renal Failure

(2011) Eduardo Vázquez et al.   CHEST

A New Risk Scheme to Predict Warfarin-Associated Hemorrhage

(2011) Margaret C. Fang et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study

(2010)   AMERICAN HEART JOURNAL

Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC)

(2010) Elsayed Z. Soliman et al.   AMERICAN HEART JOURNAL

Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review

(2010) Isla M. Ogilvie et al.   AMERICAN JOURNAL OF MEDICINE

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

(2010) Dagmar Kubitza et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

(2010) Ron Pisters et al.   CHEST

The RecordAF Study: Design, Baseline Data, and Profile of Patients According to Chosen Treatment Strategy for Atrial Fibrillation

(2009) Jean-Yves Le Heuzey et al.   AMERICAN JOURNAL OF CARDIOLOGY

Outcomes and predictors of very stable INR control during chronic anticoagulation therapy

(2009) D. M. Witt et al.   BLOOD

Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure

(2009) Jonathan P. Piccini et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

(2008) Dagmar Kubitza et al.   CURRENT MEDICAL RESEARCH AND OPINION

Rivaroxaban, an oral direct factor Xa inhibitor

(2008) Jonathan P Piccini et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

(2008) et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS